CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Policosanol +1 moredrug
Likely dose
Policosanol 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00312923
NCT00312923Phase 2Completed
CompareCT.gov

Preliminary Study of Safety and Efficacy of Policosanol

Rush University Medical Center·interventional·Posted Apr 11, 2006·Updated Jul 26, 2013

In Brief

A Phase 2 clinical trial evaluating Policosanol and Placebo for Dyslipidemia and HIV Infections. Completed, enrolled 54 participants across 1 site.

Detailed Summary

Lay Language Summary: High cholesterol levels are common in persons with HIV infection. However, conventional cholesterol-lowering medications may have harmful side effects when given to HIV-infected persons. Therefore, we plan to evaluate the safety and effectiveness of policosanol, a dietary supplement derived from sugar cane that has cholesterol-lowering properties, to lower cholesterol levels in persons with HIV infection. We hypothesize that policosanol will lower levels of LDL cholesterol ("bad" cholesterol) and raise levels of HDL cholesterol ("good" cholesterol).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia, HIV Infections
CountriesUnited States
CollaboratorsNational Center for Complementary and Integrative Health (NCCIH)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 11, 2006
Enrollment StartSep 1, 2005
Primary CompletionJul 1, 2009
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 20.2 years ago

Interventions

Policosanoldrug

20 mg of policosanol in capsular form daily

Placebodietary

Two capsules of 10 mg of microcrystalline cellulose daily